Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

UPDATE - Alliance Phama delighted with return to double-digit profit growth

Alliance Pharma lifted its annual profit by more than a tenth but said the growth rate was almost twice that stripping out anti-inflammatory steroid Deltacortril.
UPDATE - Alliance Phama delighted with return to double-digit profit growth

-- adds share price, CEO and broker comment --

Alliance Pharma (LON:APH) grew annual profit by more than a tenth but said the growth rate was almost twice that stripping out the drag of anti-inflammatory steroid Deltacortril.

The group's strategy is to “buy and build” mature prescription treatments deemed surplus to requirement by the major pharmas.

Pre-tax profits in 2013 rose 11% to £12mln on a modest rise in revenues to £45.5mln.

Deltacortril, acquired in 2006, has seen margins under pressure in recent years and since 2010 has seen an £11mln decline in its gross profit, though Alliance said it will no longer have an impact on the numbers going forward.

Turnover is also still being affected by the production problems at the maker of bladder cancer treatment ImmuCyst, Sanofi Pasteur, but Alliance expects sales to resume at the end of this year and revenues to build in 2015.

Growing demand for Hydromol helped make up for the ImmuCyst shortfall with sales of the eczema cream range 12% higher at £5.3mln.

Hydromol is now the company’s largest brand and manufacturing capacity is being expanded after demand outstripped production at one point during the year.

A cyclical peak in demand for a toxicology product also meant it made a significant contribution, while sales of Nu-Seals, the enteric-coated low-dose aspirin that is sold mainly in the Irish Republic, held up better than expected.

Broker Numis said the figures were ahead of its expectations and it upgraded its rating to ‘add’ from ‘hold’.

“The investment case hinges on delivery of meaningful acquisitions. We await further news flow in this regard but with our price target uplift from 38p to 39p…we see 18% upside from current levels”.

John Dawson, Alliance’s chief executive, said it was seeing plenty of opportunities for deals especially with many of the major groups seeking to rationalise their portfolios.

Stability of cashflow and sales were paramount in looking for assets to buy, he said, with the performacne over five years a key measure.

A five-year UK price regulation regime means it has to pay a rebate of 3.74% on sales, which will amount to £0.5mln this year, but despite this Dawson said he is “very bullish” on the current year as deal flow was healthy,finance was available while Deltacortril is “at rock bottom so that can’t do us any more damage.”  

Its joint venture in China, meanwhile, has taken a minority stake in Synthasia, which markets Swiss-made infant milk in the country.

The annual dividend got a 10% lift and the shares rose 1% to 33.8p.

View full APH profile View Profile

Alliance Pharma plc Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use